

Sun Pharma launches its novel licensed brand Fexuclue in India

The drug indicated for the treatment of Erosive Esophagitis is marketed by Daewoong Pharma and under the licensing agreement Sun Pharma is bound to make upfront and milestone payments, including royalties.



Mumbai: Indian drug maker, Sun Pharma has launched its brand Fexuclue tablets version Fexuclue, a novel potassium competitive acid blocker, indicated for the treatment of adults with Erosive Esophagitis of all

grades.

The drug is marketed by Daewoong Pharmaceutical and Sun Pharma has obtained India rights through a licensing deal under which the Korean-drug maker is entitled to upfront and milestone payments, including royalties.

"Erosive Esophagitis is a serious condition that greatly affects patients' quality of life. Despite available treatments, there remains a significant unmet need in its management but Fexuclue, is a best-in-class treatment option with the potential to bridge this gap," said Kirti Ganorkar, CEO, India Business, Sun Pharma.

In a stock exchange filing, Sun Pharma shared that, “the drug was evaluated in a double-blind, double-dummy, comparative Phase 3 study in adult Indian population and the primary efficacy measure was healing of Erosive Esophagitis which was confirmed endoscopically and was found to be well tolerated in Indian patients.”

“The study met its primary endpoint, where over 95 per cent of the patients achieved Erosive Esophagitis healing by eight weeks,” it added.

News Source:

https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/sun-pharma-launches-its-novel-licensed-brand-fexuclue-in-india/120065959?utm_source=whatsapp_web&utm_medium=social&utm_campaign=socialsharebuttons